Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial

The REACH Trial Investigators

研究成果: Article同行評審

413 引文 斯高帕斯(Scopus)

指紋 深入研究「Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial」主題。共同形成了獨特的指紋。

Medicine & Life Sciences